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Cell Transplantation for Thalassemia
Antonella Isgro`,1 Marco Marziali,1 Pietro Sodani,1 Javid Gaziev,1 Buket Erer,1 Paola Polchi,1
Katia Paciaroni,1 Andrea Roveda,1 Gioia De Angelis,1 Cristiano Gallucci,1 Cecilia Alfieri,1
Maria Domenica Simone,1 Francesco Zinno,2 Giancarlo Isacchi,2 Gaspare Adorno,3
Alessandro Lanti,3 Wilma Leti,4 Fernando Aiuti,4 Daniela Fraboni,5
Marco Andreani,6 Guido Lucarelli1To analyze immunohematologic reconstitution, particularly of natural killer (NK) cells, we evaluated 13 b-
thalassemia patients after 20 and 60 days and 1 year posttransplantation with T cell-depleted HLA-haploi-
dentical stem cells. We assessed lymphocyte and bone marrow (BM) progenitor cell phenotype and differ-
entiation capacity, spontaneous BM cytokine production, stromal cells, and stromal cell interleukin (IL)-7
production. A reduced clonogenic capability manifested at day 120. Patients had significantly lower
CD41 T cells versus controls, mainly in the CD45RA1CD62L1 subset. NKs were among the first lympho-
cytes to repopulate the peripheral blood. At day160, an increase in primitive BM progenitor cells paralleled
small increases in CD41, naı¨ve CD41, and thymic naı¨ve Th cells. A significant increase in CD41 and CD81
markers paralleled an increase in CD32CD161NKs, especially with full engraftment. In patients with stable
mixed chimerism we observed very low levels of CD31 donor chimerism early after transplant that in-
creased over time, but a stable population of high donor NK cells, suggesting a role of these cells on donor
engraftment. Stromal cells secreted less IL-7 and displayed ‘‘macrophage-like’’ morphology. Patients initially
manifested impaired stem/progenitor cell growth and differentiation capacity in parallel with altered T cell
homeostasis and a reduced T cell naı¨ve compartment. We hypothesize that T cell compartment damage
partly arises from altered newT cell production from the hematopoietic stem/progenitor cells under stromal
cytokine influence. NNK subset analysis might be useful for determining transplant outcome.
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Approximately 25% to 30% of patients with thal-
assemia could have a human leukocyte antigen
(HLA)-matched related donor. Because hematopoietic
stem cell transplantation (HSCT) is the only cure for
thalassemia, there is need to develop alternative stem
cell donation sources. We have past experience with
bone marrow (BM) transplant from alternative donors
for 29 patients with b-thalassemia major who received
phenotypically matched grafts or haploidentical grafts
mismatched for 1, 2, or 3 antigens; the results were
characterized by higher graft failure (55%) and low
thalassemia-free survival (21%) [1]. Haploidentical
HSCT (HaploHSCT) from a mismatched family
member donor offers an alternative for patients who
lack an HLA-matched donor. The main complications
are graft rejection, delayed immune reconstitution,
graft-versus-host disease (GVHD), and a higher fre-
quency of opportunistic infections. Several groups1557
1558 Biol Blood Marrow Transplant 16:1557-1566, 2010A. Isgro` et al.have overcome the HLA barrier in HaploHSCT by
administering large doses of CD341-selected stem
cells [2-4]. However, the loss of other immune
components, especially natural killer (NK) cells,
during the selection process makes this approach less
than optimal for generating antiinfection effects and
for delayed immune reconstitution, rejection, or
severe GVHD.
Haploidentical T cell-depleted HSCT from
mother to child, based on the assumption that the im-
munotolerance established during pregnancy might
help bypass the HLA disparity, is under study at our
center. Preliminary results suggest that HaploHSCT
is a realistic therapeutic option for thalassemic patients
without an HLA-identical donor. In HaploHSCT,
donor-versus-recipient NK cell alloreactivity derives
from a mismatch between donor NK clones bearing
inhibitory killer cell Ig-like receptors for self HLA
class I molecules and their HLA class I ligands on re-
cipient cells. The mechanism by which alloreactive
NK cells exert their benefits in transplantation has
been elucidated, as follows: the infusion of alloreactive
NK cells (1) ablates recipient T cells, which reject the
graft, and (2) ablates recipient dendritic cells (DCs),
which trigger GVHD, thus conferring protection
against GVHD [5]. NK cell alloreactivity also boosts
rapid rebuilding of donor adaptive immunity to infec-
tions.
In vivo development of lymphoid progenitors re-
quires a strict interaction of these cells with the BM
stromal microenvironment, which provides a rich mi-
lieu of cytokines, extracellular matrix proteins, and ad-
hesion molecules [6,7]. Impaired stromal function,
alteration of the hematopoietic growth factor
network, and abnormal apoptosis may all be involved
in impaired hematolymphopoiesis after transplant.
To investigate immunohematologic reconstitution
post transplant, we analyzed BM progenitor cell
growth and differentiation capacity, the functional
and morphologic characteristics of BM stromal cells,
and the phenotype of circulating lymphocyte subsets,
particularly NK subsets, at different times posttrans-
plant.MATERIALS AND METHODS
Patient Population
The study group consisted of 13 consecutive
b-thalassemia patients, followed as out-patients at
the Mediterranean Institute of Hematology (IME),
University of Rome ‘‘Tor Vergata.’’ They were en-
rolled for T cell-depleted HLA HaploHSCT. The
age range was 3 to 12 years (median: 5 years). All
patients received hydroxyurea (60 mg/kg) and azathio-
prine (3 mg/kg) from day 259 until day 211; fludara-
bine (30 mg/m2) from day 217 to day 211; busulfan(14 mg/kg) starting on day 210; and cyclophospha-
mide (200 mg/kg), thiotepa (10 mg/kg), and antithy-
mocyte globulin (ATG-Fresenius S) (12.5 mg/kg)
daily from days 25 to 22, followed by CD341
T cell-depleted (CliniMacs System, Germany), granu-
locyte colony stimulating factor (G-CSF)-mobilized
peripheral blood (PB) stem cells from their HLA-
haploidentical mother.
T and B cell depletion was carried out with
CD341-coated magnetic microbeads and the
CliniMACS device (Miltenyi Biotec) from PB and
BM of donors (the mothers) and resulted in grafts con-
sisting of stem cells and effector cells (NK cells, mono-
cytes) with the addition of BM mononuclear cells
(BMMCs) (3  105/kg of the recipient). The purity
of CD341 cells after MACS sorting was 98% to 99%.
Patients received cyclosporine after transplant for
GVHD prophylaxis during the first 2 months after
the BM transplantation.
Signed informed consent was received for the pa-
tients before transplantation, and all procedures were
performed according to our center’s established proto-
cols. The study protocol was approved by the center’s
institutional review board.
Flow-Cytometric Analysis of Peripheral Blood
Mononuclear Cells (PBMCs)
Whole-blood phenotype analysis consisted of lysing
500 mL blood with 10 mL of Ortho-mune Lysing
Reagent (Ortho Diagnostic Systems Inc., Raritan, NJ,
USA) at room temperature, and washing and labeling
with a cocktail of 4 monoclonal antibodies (mAbs) for
30 minutes at 4C. Anti-CD3-fluorescein isothiocya-
nate (FITC), anti-CD4-allophycocyanin (APC), anti-
CD8-peridinin chlorophyll protein (PerCP), anti-CD56
peridinin chlorophyll protein (PerCP), anti-CD16
APC, anti-CD45RA-FITC, anti-CD62L-phycoerytrin
(PE), and anti-CD19-PE were purchased from Becton
Dickinson (San Diego, CA, USA). To identified thy-
mic naive Th cells, we used the following antibodies
as previously described [8]: anti-CD4-PerCP, anti-
CD45RA-FITC, and anti-CD31-PE, all from Becton
Dickinson. After staining, cells were washed once in
phosphate-buffered saline (PBS) containing 2% fetal
bovine serum and analyzed on a FACSCalibur cyto-
fluorometer (Becton Dickinson, Mountain View, CA,
USA) using Cell Quest software. Absolute lymphocyte
counts were calculated by a standard hemocytometric
technique.
Preparation of BMMCs
BM aspirates were initially collected into a tube
containing ethylenediaminetetraacetic acid (EDTA)
as the anticoagulant. The BM samples were diluted
1:3 with PBS 1 plus EDTA 5 mM, then separated af-
ter centrifugation by Ficoll (Lymphoprep, Nycomed
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1640 medium supplemented with 10% fetal calf serum
(FCS), L-glutamine (2 mmol/L), and penicillin (250
U/mL) (all from Life Technologies s.r.l., Milan, Italy).
Colony-Forming Cell (CFC) Assay and Long-
Term BM Cultures (LTBMC)
BMMCs (1  105) were plated in duplicate cul-
tures in 1 mL methylcellulose assay medium contain-
ing recombinant human (rHu) erythropoietin (3 U/
mL), rHu stem cell factor (50 ng/mL), rHu granulo-
cyte/macrophage colony stimulating factor (GM-
CSF; 10 ng/mL), and rHu interleukin-3 (IL-3, 10
ng/mL) (BIOPSA, Stem Cell Technologies, Vancou-
ver, Canada). According to standardized morphologic
criteria, the growth of the multipotent hemopoietic pro-
genitor was evaluated as colony forming unit (CFU)
granulocyte-, erythrocyte-, monocyte-megakaryocyte
(CFU-GEMM, or CFU-MIX), a burst-forming unit
erythroid (BFU-E), a CFU-erythroid (CFU-E), or
a CFU granulocyte-monocyte (CFU-GM) after 2
weeks of incubation at 37C in an atmosphere of 5%
CO2.
To analyze the most immature progenitors and the
stem cell compartment, we used LTBMCs. Stromal
cell cultures and determination of long-term culture-
colony-forming cell numbers were performed accord-
ing to a modification of previously described methods
[9]. The murine BM stromal cell line M210B4 was cul-
tured until cell confluence, then trypsinized, irradiated
(8000 rad), washed, and placed in 6-well plates. Total
BMMCs (1  106 cells, in duplicate cultures) were ap-
plied on the preestablished, irradiated stromal feeder
layers and cultured at 37C for 5 weeks.
The half-medium liquid was changed weekly. Af-
ter 5 weeks, the nonadherent and adherent cells were
harvested by treatment with trypsin (Life Technolo-
gies), washed, and replaced in duplicate in methylcel-
lulose to evaluate the number of cells able to
determine secondary colonies. The number of CFCs
generated after 5 weeks of cultures on stromal cells
gives an indirect but consistent measurement of the
content of LTC-initiating cells (LTC-ICs).
Spontaneous Cytokine Production from BMMC
Cultures
To evaluate the cytokine production at BM level,
BMMC short-term cultures were performed with
freshly collected BM samples. Briefly, isolated
BMMCs were cultured in RPMI 1640 medium supple-
mented with 10% FCS, L-glutamine (2 mmol/L), and
penicillin (250 U/mL) in 5% CO2 atmosphere at
37C, in the absence of stimuli, to verify the spontane-
ous production of cytokines IL-2 and tumor necrosis
factor (TNF)-a. After 24 hours of culture, superna-
tants were collected and measurement of cytokineswas performed by ELISA, according to the
manufacturer’s instructions (R&D Systems, Minneap-
olis, MN, USA). For each cytokine determination
a standard curve was generated.
BM Stromal Cell Characterization by
Immunohistochemistry
BMMCs were cultured in tissue culture chamber
slides (Falcon, Lincoln Park, NJ, USA) in Iscove’s
modified Dulbecco’s medium (IMDM) (Gibco BRL
Life Technologies, Gaithersburg, MD, USA) supple-
mented with 20% FCS, 100 IU/mL penicillin-
streptomycin, and 100 IU/mL glutamine, at 37C in
humidified air at 5% CO2. At weekly intervals, cultures
were fed by demipopulation of the nonadherent cells
and replacement of 500 mL of fresh supplemented
IMDM. Cultures were maintained until stromal con-
fluence (3-4 weeks) and then analyzed by immunohis-
tochemistry. Stromal cells were fixed with a mixture of
50:50 acetone:ethanol for 30 minutes and then incu-
bated for 30 minutes with the following primary anti-
bodies: anti-CD68 (1:200) and anti-CD14 (5:100) as
macrophage markers; anti-CD34 (1:25) as a progenitor
cell marker; anti-S100 (1:1000) as an adipocyte
marker; and antivimentin (1:50) as a mesenchymal
marker (all from DAKO, Dakopatts, Copenhagen,
Denmark). Samples were then stained to amplify and
detect the signal, according to the manufacturer’s in-
structions, using an immunoperoxidase technique
(DAKO LSAB Kit-peroxidase, Dakopatts). Slides
were subsequently analyzed using light microscopy.
Spontaneous IL-7 Production from BM Stromal
Cultures
BMMCs were cultured in 24-well plates in IMDM
supplemented with 10% FCS, 10% horse serum, 100
IU/mL penicillin-streptomycin, 100 IU/mL glutamine,
and 1026 M hydrocortisone sodium succinate (Sigma,
St. Louis, MO, USA), at a concentration of 1  106
cells/mL in a total volume of 2 mL per well. The plates
were incubated at 37C in humidified air at 5% CO2.
At weekly intervals, cultures were fed by demipo-
pulation of the nonadherent cells and replacement of
500 mL of fresh, supplemented IMDM. Cultures
were maintained until stromal confluence (3-4 weeks),
then cells were collected by trypsinization and cultured
at a concentration of 1 106 cells/mL in a total volume
of 1 mL per well. Supernatants were then collected af-
ter 24 h of culture and measurements of cytokine IL-7
were performed by ELISA, according to the manufac-
turer’s instructions for its ultrasensitive kit (R&D
Systems, Minneapolis, MN, USA).
Statistical Analysis
Nonparametric statistics were used (Mann-Whitney,
Wilcoxon test) for unpaired and paired comparisons
1560 Biol Blood Marrow Transplant 16:1557-1566, 2010A. Isgro` et al.between the parameters analyzed. A P value \ .05
was considered significant. Statistical analyses were
performed using Statview 5.0 software (SAS Insti-
tute, Cary, NC, USA).RESULTS
Donors
Family members were assessed for HLA compatibil-
ity by serologic methods or by high-resolution molecu-
lar analysis. All donors were identical for 1 haplotype and
incompatible at 3 loci (HLA-A, -B, -DR) of the other.
The stem cell dose was achieved with a median of 3
leukaphereses (range: 1-5). The donors showed in PB
in mean 46.1% 6 6.4% (1151 6 650/mm3) CD41 T
cells, 25.5% 6 5.3% (671 6 425/mm3) CD8 T cells
and 13.2% 6 3.5% (275 6 107/mm3) CD191. The
percentage of donor’s NK cells (CD3–CD161CD561)
was in mean 11.1% 6 8.6% (167 6 31.7/mm3). No
correlation was observed between PB T cells of donors
and engraftment in patients.Grafts
Median infused cell doses per kilogram of recipient
body weight were as follow: NC 0.208  109/kg
(range: 0.009-0.650  109/kg); CD341 18.3  106/kg
(range: 7.35-28.2  106/kg); CD31 0.736  106/
kg (range: 0.008-2.38  106/kg); CD41 0.21  106/
kg (range: 0.081-0.431  106/kg); CD81 0.531 
106/kg (range: 0.08-1.46  106/kg); CD191 0.622 
106/kg (range: 0.032-2.460  106/kg); NK cells
0.403  106/kg (range: 0.201-0.821  106/kg). No
correlation was observed between infused cell doses
and engraftment in patients.0
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Figure 1. Transient engraftment of donor cells in a thalassemia patient after H
cells starting from 13 days post-haploHSCT. At 18 days post-haploHSCT, we d
peripheral blood (DNA PB) and bone marrow (DNA BM) with identification
blood cells (WBCs) increased until 22 days, then we observed a progressivel
PB, DNA BM 0% donor cells).Engraftment
After Haplo HSCT, 6 of 13 patients manifested full
engraftment, 3 of 13 were mixed chimerism (MC), and
4 of 13 rejected the transplant. Eleven patients are alive.
Two patients died after full engraftment, 1, 6 months
after BM transplant for Epstein-Barr virus-related
central nervous system diffuse large B-cell lymphoma,
and 1 from a cytomegalovirus-related opportunistic
infection. Seven patients are alive and disease free
with a median follow up of 15 months.
In patients who showed allogeneic reconstitution,
median time for granulocyte recovery was 13 days
(range: 11-17 days), whereas median time for a self-
sustained platelet recovery was 12 days (range: 9-17
days). In 4 cases, donor BM was rejected with complete
autologous reconstitution and return to pretransplant
clinical status. In these cases, rejection occurred after
transient engraftment of donor cells, as reported in
Figure 1. MC was classified, according to the propor-
tion of residual host cells present in the recipient, into
MC level 1 (residual host cells\10%), MC level 2 (re-
sidual host cells between 10% and 25%), and MC level
3 (residual host cells .25%). Three patients experi-
enced a status of mixed chimerism level 3 early after
BM transplantation (BMT), which became persistent
when observed respectively at 14, 38, and 42 months
after the transplant. To define the condition of MC
better, we analyzed the proportion of donor engraft-
ment in different lymphoid subsets at different times
after BMT. Figure 2 reported the mixed chimerism
condition in each of 3 patients. The recipients with
full donor chimerism had 100% of CD31 donor cells
and 100% of donor NK cells, stable over time. The in-
dividuals who had stable mixed chimerism, showed to
have very low levels of CD31 donor chimerism early%89 MBhsi
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Figure 2. Mixed chimerism in 3 patients after haploHSCT. Proportion of donor engraftment in different lymphoid subsets (CD31 and NK cells) at
different times after BMT in 3 patients (PT.1, PT. 2, PT. 3).
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lel with high and stable levels of donor NK population,
suggesting that donor NK cells might have promoted
tolerance and donor engraftment. The levels of immu-
nosuppression were uniform in all patients. No patient
developed GVHD and all patients came off immuno-
soppression at the same time.Immunologic and Hematologic Data on PBMCs
At day 20 posttransplant, patients had significantly
lower CD41 T cell numbers in comparison to normal
value (4% 6 5.4% versus 47.5% 6 6%, respectively;
16.7 6 31.7/mm3 versus 410-1580/ mm3), mainly inthe CD45RA1CD62L1 (naive phenotype) subset
(1.6% 6 1.3% in patients versus 52% 6 12% normal
value). There was a significant decrease in peripheral
CD45RA1CD311 Th cells (thymic naive Th cells)
(on average 1%6 0.3% in patients versus 37%6 10%
normal value), whereas CD81 T cell numbers did not
statistically differ between patients and normal value
(17%6 20% versus 20%6 7%). All patients displayed
reduced numbers of B cells versus normal value, and 5
patients had only 0% to 1% of control levels of CD191
cells.
At day 60 posttransplant, no significant change was
observed in the percentages of CD41 T cells, naı¨ve
CD41 cells, thymic naı¨ve Th cells, or CD81 T cells
1562 Biol Blood Marrow Transplant 16:1557-1566, 2010A. Isgro` et al.(5.8%6 3.5%, 48%6 32.4/mm3 CD41; 3.2%6 1.5%
naı¨ve CD41; 2.9%6 0.5% CD311 and 16.8%6 15%,
150.2 6 161.9/mm3 CD81).
Compared with normal values, thalassemia patients
showed a significant increase in CD41 cell activation
markers (CD95, HLA-DR, and CCR5), observed after
60 days posttransplant. Only a year after transplant did
we identify a partial normalization of CD31, CD41,
CD81, and CD191 compartments (Figure 3).
NK cells were among the first lymphocytes to re-
populate the PB, and up to 45% of these cells were
CD32CD56bright (mean 45.6% 6 35%, 189.6 6
192.6/mm3), whereas CD32CD161NK cells were re-
duced (mean 15.2% 6 16.6%, 56.3 6 73.8/mm3). In-
terestingly, a direct correlation was observed between
the percentages of the CD32CD561CD161 NK sub-
set and the BM engraftment with mean values of 78%
6 15.3% CD561CD161 in the 6 patients with full en-
graftment, 14% 6 5.1% in the 3 patients with a stable
mixed chimerism after transplant (70%-80% of donor
cells), and 1.4%6 1.3% in the 4 patients with rejection
(Figure 4a). This correlation was principally observed
for the CD32CD56bright compartment (mean 67.9%
6 27% in full engraftment versus 44.3% 6 19.3% in
mixed chimerism and 2.4% 6 1.9% in patients with
rejection) (Figure 4b). Interestingly, in patients with
mixed chimerism at 120 days, the NK compartment
was represented principally by CD32CD161 (with cy-
totoxic functions) (mean 30.3 6 16.2 versus 16.5 6 16
with full engraftment and 1.9 6 3.3 in rejection)
(Figure 4c). In all patients, the origin of the NK subsets
was the mothers.
At day 160, we observed an increase in the
CD32CD161 NK cells (potent cytotoxic effector
cells), especially in patients with full engraftmentFigure 3. Mean immune indicator values before and after HaploHSCT. The
(CD31, CD41, CD81) and B lymphocytes (CD191) after 20 days, 60 days, an(mean 31.5% 6 21.7% versus 14.5% 6 10% in mixed
chimerism versus 0.7% 6 0.4% in patients with rejec-
tion) (Figure 4).
CFC Assay and LTBMCs
As reported in Figure 5, the reduced clonogenic
capability observed at day 20, showed an initial in-
crease of committed progenitor cells at day 160 after
transplant. This finding was also observed on primitive
BM progenitor cells compartment after 2 months
of transplant (1.8 6 1 at 20 days versus 3.3 6 2.4
LTC-CFC/106 BMMCs; P 5 .0022).
Measurements of Spontaneous Cytokine
Production in BMMC Cultures
In vitro production of IL-2 and TNF-a by
short-term culture of BMMCs was determined in thal-
assemia patients 20 and 60 days posttransplant. The
spontaneous production of IL-2 and TNF-a was
significantly decreased in patients 60 days posttrans-
plant (18.6 6 9.2 pg/mL at 20 days versus 8.9 6 5
pg/mL at 60 days IL-2; P 5 .00015, and 11.9 6 4.1
pg/mL at 20 days versus 4.5 6 3.3 pg/mL at 60 days
TNF-a; P 5 .0003).
Immunohistochemistry of BMStromal Cells and
IL-7 Production
Next, we generated stromal cell layers from
BMMCs of patients. The stromal layers cultured on
chamber slides were positive for CD68, vimentin,
and CD14 but negative for S100 and CD34, indicating
that they were preferentially of the macrophage/
monocyte lineage. Upon light microscopy examination,
the majority (75%) of these cells appeared asbars represent the mean value (6SD) of percentages of circulating T
d 1 years of transplant in b-thalassemia patients.
Figure 4. NK subsets after haploHSCT. The bars represent the mean value of percentages of CD32CD561CD161 (A), CD32CD561 (B), and (C)
CD32CD161 in full engraftment, in mixed chimerism, and in rejection 20 and 60 days posttransplant.
Biol Blood Marrow Transplant 16:1557-1566, 2010 1563Bone Marrow Analyses Posttransplant in Thalassemiamoderately large and frequently rounded, with abun-
dant cytoplasm at day 120. At day 160, we observed
a tendency to normalization of stromal composition
near that of normal subjects, in which about 90% of
the stromal cells exhibited a different morphology
characterized by an irregular or spindle shape and
branching cytoplasmic processes (fibroblast-like).
Stromal cells from patients spontaneously pro-
duced lower levels of IL-7 compared with normal
value (0.3 6 0.1 pg/mL versus 0.8 6 0.1 pg/mL, re-
spectively; P 5 .02).DISCUSSION
HSCT offers the only chance of cure for patients
with thalassemia. Haploidentical transplantation may
extend this possibility to the 50% to 60% of the pa-
tients who lack a suitably matched familial donor or
an HLA-identical unrelated donor. The presence of
fetal cells in maternal blood and of maternal cells in fe-
tal blood (fetomaternal microchimerism) suggests that
immunologic tolerance may exist between mother and
offspring [10,11].
We have reported [12] the results of BM transplan-
tation in children with acute leukemia in relapse
resistant to chemotherapy, where their haploidentical
mother was used as the donor of nonmanipulatedbone marrow. The combination of a megadose of pu-
rified CD341 cells and a highly immunomyeloablative
conditioning regimen is crucial for overcoming the
barrier of residual antidonor cytotoxic T-lymphocyte
precursors in T cell-depleted mismatched transplants
[13] and the addition of BMMCs (including NK cells,
mesenchymal stem cells, T cells) to a T cell-depleted
allograft may help promote engraftment and control
GVHD. The reason of adding back BMMCs of 3 
105/kg in our patients was based on the assumption
that a minimal threshold of lymphocytes for develop-
ing of GVHD was 105/kg [14]. The simultaneous
addition of BMMCs (including stem cells, NK cells,
monocytes, DCs, mesenchymal cells), may have a po-
tential role for immunotolerance and engraftment.
BM could be a site of T cell priming, because the anti-
gen is accessible for presentation by BM DCs. It was
described that antigen-specific CD41 and CD81 T
cells home to BM after antigen challenge in the periph-
ery and are maintained there over long periods of time
[15]. In addition, an important role for CD41T cell on
BM engraftment is described, not only promoting
rejection of the few host cells after the conditioning reg-
imen, but also allowing efficient HSC differentiation
and reconstitution [16]. In the presence of antigen-
primed CD41 T cells, cytokines are secreted and
terminal differentiation of hematopoietic committed
Figure 5. Clonogenic progenitor cells in thalassemia patients. The bars represent the mean number (6SD) of colonies obtained by 100,000 BMMCs
plated in methylcellulose (CFC assay) from thalassemia patients 120 and 160 days posttransplant. The growth of CFU-GEMM, BFU-E, CFU-E, and
CFU-GM was evaluated according to standardized morphologic criteria.
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cells are absent or their cognate antigens are not avail-
able, hematopoiesis is defective, resulting in immature
cell accumulation in the BM or leukopenia in the
PB [16].
Haploidentical transplantation is associated with
major posttransplant immune deficiency, resulting in
significant morbidity and mortality from infection.
Immune reconstitution posttransplant and mainte-
nance of homeostasis in BM require a well-balanced
interaction between the hematopoietic cells and the
immune system. The immune system may modulate
the function of BM hematopoietic progenitor cells
and/or their microenvironment, either by inflamma-
tory cytokine production or by cell-to-cell interactions
[17]. Delayed immune reconstitution posttransplant
may be associated with a variety of functional and
immunophenotypic abnormalities at the BM level be-
cause of augmented local production of inflammatory
cytokines, increased T cell activation, or intrinsic
hematopoietic and stromal cell abnormalities.
Quantitative and functional defects in hematopoi-
etic progenitor cells were observed in our patients in
the initial phase posttransplant, as indicated by an
altered clonogenic potential of BM-committed pro-
genitor cells and a significant reduction in primitive
progenitors. These abnormalities may represent either
an intrinsic progenitor cell defect or secondary
progenitor cell damage in response to an underlying
inflammatory process within the BM microenviron-
ment. The patients displayed an altered BMMC
cytokine production, characterized initially by in-
creased levels of TNF-a. This cytokine patternchanged after 60 days posttransplant, with a tendency
to normalization.
These findings correlated with a significant de-
crease in total lymphocyte counts and depletion of
CD41 T cells expressing predominantly the CD45
RA1CD62L1 phenotype. Also, the CD41CD45
RA1CD311 T cell subset was significantly reduced
in our cohort, suggesting thymus involvement in these
patients. Furthermore, we cannot rule out a defective
egress of naı¨ve T lymphocytes from the thymus [18].
Indeed, it is possible that the T cell defect in thalasse-
mia patients may occur at multiple levels, including
egress from the thymus.
In vivo and in vitro, hematolymphopoiesis occurs
in association with the complex network of cell types
found in the stroma, including nonhematopoietic
(fibroblasts, adipocytes, and endothelial cells) and
hematopoietic cells (macrophages and T cells). Pro-
genitor cell growth and differentiation depend on their
interaction with stromal cells. Low levels of cytokine
production can be more effective when local concen-
tration is increased by cell-cell contacts and by the
binding of cytokines to the extracellular matrix
[19,20]. The prevalence of macrophage-like cells in
long-term BM culture, rather than the typical ‘‘fibro-
blast-like’’ cells, suggests an altered composition of
the BM stroma, possibly linked to an underlying in-
flammatory process within the BM microenvironment.
A central function of stromal cells is IL-7 produc-
tion [21]. Recent evidence shows that IL-7 acts as a mas-
ter regulator of T cell homeostasis, expanding both the
naive and memory T cell populations [22,23]. IL-7 pri-
marily acts as a growth and antiapoptotic factor for B
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the beginning of B and T lymphopoiesis starting from
stem cells. The patients exhibited altered stromal cyto-
kine production at 20 days posttransplant, character-
ized by decreased IL-7 levels. We can hypothesize
that the delayed immunoreconstitution of the T cell
compartment may be initially the result of altered gen-
eration of new T cells arising from hematopoietic pro-
genitor cells with the interaction of impaired stromal
cell function. Based on these results, it can be hypoth-
esized that therapeutic administration of some cyto-
kines (ie, IL-2 plus IL-7) and or mesenchymal stem
cells (MSCs) might form a future strategy supporting
T cell development posttransplant.
Because MSCs are the precursors of BMSCs, it was
originally thought that they could facilitate hemato-
poietic stem cell (HSC) engraftment [24-26]. MSC
infusion, in addition to being safe [21], improved the
success of HSC transplantation and the clinical out-
come [27]. When we added maternal MSCs in vitro
to BMMCs of the daughter, we observed a significant
increase of the more immature progenitor cells in the
LTC-IC assay (data not shown), suggesting a role
for MSCs in facilitating engraftment.
NK CD561bright cells develop more rapidly than
other lymphocytes, but CD32CD161 NK cells (with
cytotoxic potential) require more prolonged exposure
to maturation factor (IL-2) in the BM. No significant
correlation has been observed between cell doses in-
fused after T cell depletion or immunologic character-
istics of the donors and engraftment in patients, but
interestingly, we observed higher percentages of NK
CD561bright cells only 20 days posttransplant in pa-
tients with full engraftment, suggesting a role for
newly generated NK cells in improved engraftment
and in prevention of rejection by an attack of the
host lymphohematopoietic cells. The higher percent-
ages of CD32CD161 in mixed chimerism patients
may have a possible role in control of host-cell escape
and in maintaining the chimerism condition. The
recipients with full donor chimerism had 100% of
CD3 donor cells and 100% of donor NK cells, stable
over time. The situation was different in patients
with mixed chimerism who had high level of donor
NK cells and low donor CD31 cells during the first
month after transplantation. Subsequently, the
number of donor CD31 cells progressively increased,
probably because of donor NK cells promoted
tolerance and engraftment.
Pioneering studies by Velardi and colleagues [28]
revealed that patients with acute myelogenous leuke-
mia transplanted from an NK alloreactive donor
benefited from higher rates of engraftment and re-
duced rates of GVHD. The virtual abrogation of
GVHD may be a consequence of NK cell-mediated
killing of recipient antigen-presenting cells [29,30].
In our group, no patient showed signs of GVHDposttransplant [31]. The beneficial effects could also
be related to depletion of patient antigen-presenting
cells and facilitation of engraftment as a result of the
killing of T cells, removing patient lymphohemato-
poietic cells, and production of growth factors re-
quired for engraftment and for accelerating recovery
of myelopoiesis. Our studies may also suggest NK sub-
set analysis as a useful measure of transplant outcome.ACKNOWLEDGMENTS
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